INTRODUCTION

Patient Characteristics
• 573,112 individuals were identified based on an incident diagnosis of type 2 diabetes.
-23% met the continuous medical and pharmacy eligibility criteria • Patients were similar in age; the majority of patients in the controlled HbA1c and no HbA1c cohorts were female (Table 1) .
RESULTS
• The objective of this study was to evaluate how compliance with HbA1c testing frequency varies based on initial HbA1c results.
OBJECTIVE
• This analysis was limited to patients with commercial health coverage and with continuous enrollment for at least one calendar year during the study period; these results may not be generalizable to patients with other insurance or without health insurance coverage.
• These results are not adjusted to account for differences in general health and/or diabetes severity.
LIMITATIONS
• In this analysis less than half of newly diagnosed patients had evidence of a HbA1c test; evidence of subsequent testing was suboptimal among patients with initially good glycemic control but relatively high among those with initially poor glycemic control.
• Compliance with recommended timing for HbA1c testing is suboptimal in the majority of patients regardless of initial glycemic control.
• Importance of regular HbA1c evaluation should continue to be part of patient education -particular for patients who may initially appear to have favorable glycemic control. 
Study Population
• The MarketScan® Treatment Pathways tool was used to select the study patients and to describe characteristics of the target population.
• Individuals identified as having newly diagnosed type 2 diabetes meeting the following criteria were selected for study inclusion: -Diabetes diagnosis (ICD-9-CM 250.x0 or 250.x2) between July 1, 2010 and October 31, 2012 which was established as the index date -Continuous medical, pharmacy and laboratory eligibility 6 months prior to and 12 months post diabetes diagnosis.
• Patients cohorts were created based on first HbA1c test value (< 7.0%
[controlled], ≥7.0% [uncontrolled] , no evidence of HbA1c testing) within 120 days of diabetes diagnosis (30 days prior and 90 days following HbA1c test).
Outcomes and Analysis
• Evidence of HbA1c testing among newly diagnosed type 2 diabetes patients was reported.
• Presence of subsequent HbA1c testing, including test result and time to test were evaluated for cohorts with evidence of initial HbA1c test. • Mean time to subsequent HbA1c test (and result) among initially controlled patients was 231 days for patients with a HbA1c value < 7.0% and 370 days for patients with a HbA1c value ≥ 7.0% (Figure 2) .
METHODS
RESULTS (CONT'D)
• Mean time to subsequent HbA1c test (and result) among initially uncontrolled patients was 238 days for patients with a HbA1c value < 7.0% and 212 days for patients with a HbA1c value ≥ 7.0% (Figure 3 ). • All pairwise differences were statistically significant (p<0.0001).
